이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

PICAROS - 스페인의 1L CLL에 대한 Acalabrutinib RWE (PICAROS)

2026년 11월 3일 업데이트: AstraZeneca

아칼라브루티닙의 1차 사용과 스페인에서의 실제 결과를 설명하는 만성 림프구성 백혈병을 앓고 있는 이전에 치료를 받지 않았거나 1세대 BTKi 불내성 환자에 대한 비개입적 코호트 연구: PICAROS 연구

This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

연구 개요

상태

모병

정황

상세 설명

This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who received treatment with acalabrutinib for the first time in Spain.

It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

For the cohort 1, the start of acalabrutinib treatment (index date) was prior to the first site initiation visit. For both cohorts 1 and 2, the clinical decision of starting patient on acalabrutinib has to independently occur prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to approximately 32 months from the first site initiation visit for cohort 1, and approximately 25 months after the inclusion of the last patient in the cohort 2. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.

연구 유형

관찰

등록 (추정된)

315

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Andalusia
      • Almería, Andalusia, 스페인, 4009
        • 모병
        • Research Site
      • Córdoba, Andalusia, 스페인, 14004
        • 모병
        • Research Site
      • Granada, Andalusia, 스페인, 18014
        • 모병
        • Research Site
      • Jaén, Andalusia, 스페인, 23007
        • 모집하지 않고 적극적으로
        • Research Site
      • Marbella, Andalusia, 스페인, 29603
        • 모집하지 않고 적극적으로
        • Research Site
      • Málaga, Andalusia, 스페인, 29010
        • 모집하지 않고 적극적으로
        • Research Site
      • Seville, Andalusia, 스페인, 41013
        • 모병
        • Research Site
    • Aragon
      • Zaragoza, Aragon, 스페인, 50009
        • 모병
        • Research Site
      • Zaragoza, Aragon, 스페인, 50009
        • 모집하지 않고 적극적으로
        • Research Site
    • Balearic Islands
      • Palma de Mallorca, Balearic Islands, 스페인, 7010
        • 모집하지 않고 적극적으로
        • Research Site
      • Palma de Mallorca, Balearic Islands, 스페인, 7198
        • 모집하지 않고 적극적으로
        • Research Site
    • Basque Country
      • Donostia / San Sebastian, Basque Country, 스페인, 20014
        • 빼는
        • Research Site
      • Galdakao, Basque Country, 스페인, 48960
        • 빼는
        • Research Site
    • Canary Islands
      • Las Palmas de Gran Canaria, Canary Islands, 스페인, 35016
        • 모집하지 않고 적극적으로
        • Research Site
      • Las Palmas de Gran Canaria, Canary Islands, 스페인, 35019
        • 모집하지 않고 적극적으로
        • Research Site
      • San Cristóbal de La Laguna, Canary Islands, 스페인, 38320
        • 모병
        • Research Site
    • Cantabria
      • Santander, Cantabria, 스페인, 39008
        • 모집하지 않고 적극적으로
        • Research Site
    • Castille and León
      • Salamanca, Castille and León, 스페인, 37007
        • 모집하지 않고 적극적으로
        • Research Site
      • Segovia, Castille and León, 스페인, 40002
        • 모집하지 않고 적극적으로
        • Research Site
      • Valladolid, Castille and León, 스페인, 47003
        • 모집하지 않고 적극적으로
        • Research Site
      • Valladolid, Castille and León, 스페인, 47012
        • 모집하지 않고 적극적으로
        • Research Site
    • Castille-La Mancha
      • Guadalajara, Castille-La Mancha, 스페인, 19002
        • 모병
        • Research Site
      • Toledo, Castille-La Mancha, 스페인, 45004
        • 모집하지 않고 적극적으로
        • Research Site
    • Catalonia
      • Barcelona, Catalonia, 스페인, 8003
        • 모집하지 않고 적극적으로
        • Research Site
      • Barcelona, Catalonia, 스페인, 8025
        • 모집하지 않고 적극적으로
        • Research Site
      • Barcelona, Catalonia, 스페인, 8035
        • 모집하지 않고 적극적으로
        • Research Site
      • Barcelona, Catalonia, 스페인, 8036
        • 모집하지 않고 적극적으로
        • Research Site
      • Granollers, Catalonia, 스페인, 8402
        • 모집하지 않고 적극적으로
        • Research Site
      • L'Hospitalet de Llobregat, Catalonia, 스페인, 8908
        • 모집하지 않고 적극적으로
        • Research Site
      • Lleida, Catalonia, 스페인, 25198
        • 모집하지 않고 적극적으로
        • Research Site
      • Terrassa, Catalonia, 스페인, 8221
        • 모집하지 않고 적극적으로
        • Research Site
    • Galicia
      • Ourense, Galicia, 스페인, 32005
        • 모병
        • Research Site
      • Santiago de Compostela, Galicia, 스페인, 15706
        • 모집하지 않고 적극적으로
        • Research Site
      • Vigo, Galicia, 스페인, 36312
        • 모병
        • Research Site
    • Madrid
      • Madrid, Madrid, 스페인, 28006
        • 모병
        • Research Site
      • Madrid, Madrid, 스페인, 28031
        • 모집하지 않고 적극적으로
        • Research Site
      • Madrid, Madrid, 스페인, 28034
        • 모집하지 않고 적극적으로
        • Research Site
      • Madrid, Madrid, 스페인, 28905
        • 모집하지 않고 적극적으로
        • Research Site
      • Madrid, Madrid, 스페인, 28911
        • 모집하지 않고 적극적으로
        • Research Site
      • Madrid, Madrid, 스페인, 28040
        • 모병
        • Research Site
      • Madrid, Madrid, 스페인, 28041
        • 모병
        • Research Site
      • Madrid, Madrid, 스페인, 28046
        • 모병
        • Research Site
      • Majadahonda, Madrid, 스페인, 28222
        • 모집하지 않고 적극적으로
        • Research Site
    • Murcia
      • El Palmar, Murcia, 스페인, 30120
        • 모집하지 않고 적극적으로
        • Research Site
      • Murcia, Murcia, 스페인, 30008
        • 모병
        • Research Site
    • Principality of Asturias
      • Oviedo, Principality of Asturias, 스페인, 33011
        • 모집하지 않고 적극적으로
        • Research Site
    • Valencia
      • Alicante, Valencia, 스페인, 3010
        • 모병
        • Research Site
      • Valencia, Valencia, 스페인, 46010
        • 모집하지 않고 적극적으로
        • Research Site
      • Valencia, Valencia, 스페인, 46014
        • 모집하지 않고 적극적으로
        • Research Site
      • Valencia, Valencia, 스페인, 46026
        • 모집하지 않고 적극적으로
        • Research Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

The study aims to include approximately 315 patients in the cohort 1 and 103 patients in the cohort 2 who started acalabrutinib for the first time for the treatment of their CLL. To minimize selection biases, all patients (alive or deceased) identified on acalabrutinib will be eligible for inclusion into the study. These patients will be included from approximately 50 hospitals distributed throughout Spain.

설명

Inclusion Criteria:

  • Age ≥18 years old at starting acalabrutinib treatment.
  • Diagnosis of CLL.
  • Start of acalabrutinib treatment (index date) as per the CLL SmPC:
  • in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit (cohort 1).
  • in treatment-naïve CLL patients for the fixed-duration treatment combination of acalabrutinib plus venetoclax (with or without obinutuzumab) according to routine clinical practice from the EMA approval (i.e., 2 June 2025) (cohort 2).

Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.

  • Informed consent (for alive patients).

Exclusion Criteria:

  • Enrolled in any clinical trial during acalabrutinib treatment.
  • Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: OTHER

코호트 및 개입

그룹/코호트
Cohort 1

Patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit as per routine clinical practice, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression.

Cohort 2

Patients with first-line fixed-duration acalabrutinib use with venetoclax in routine clinical practice.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).
기간: 24 months after treatment initiation (cohort 1).

Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).

In addition to this outcome measured in the overall cohort, it will also be assessed by the following factors:

  1. the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression),
  2. presence/absence of risk factors (i.e., del17p, TP53 mutation, and unmutated IGHV).
  3. cardiovascular comorbidities (yes/no).
24 months after treatment initiation (cohort 1).
Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)
기간: From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

rwORR (i.e., the proportion of patients that achieved complete or partial response) achieved until the end of the observational period for first-line fixed-duration acalabrutinib therapy as assessed by the treating physician (cohort 2). Complete response may include complete response, complete response with incomplete marrow recovery, or unconfirmed complete response (marrow biopsy not performed). Partial response may include partial response, or partial response with lymphocytosis. The rwORR will be assessed by the treating physician in routine clinical practice, including the use or not of the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. The end of observational period for first-line fixed-duration combinations of acalabrutinib is defined as the start date of a subsequent line therapy or study end date, whichever comes first.

From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

2차 결과 측정

결과 측정
측정값 설명
기간
Acalabrutinib±venetoclax doses (cohorts 1 and 2).
기간: At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax doses (e.g., starting does and dose adjustments), overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, doses (e.g., starting dose, dose adjustments, maximum dose achieved) and reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the time to reach the maximal dose.

At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Patients with acalabrutinib±venetoclax dose adjustments (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %) (cohorts 1 and 2).
기간: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax dose adjustments, temporary interruptions, and permanent discontinuations, overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In patients with regimen modifications within cohort 2, the proportion of patients with these regimen modifications and the time from treatment initiation to the regimen modification within same line therapy prior to progression (e.g., treatment duration and number of cycles prior to the modification, and reason for the modification). In cohort 2, temporary interruptions, permanent discontinuations, and their reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the proportion of patients requiring dose reductions after achieving maximum dose.

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment duration in months (cohorts 1 and 2).
기간: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Treatment duration (cohorts 1 and 2), overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, also median number of completed cycles and the proportion of patients who complete 14 cycles.

Baseline patient characteristics associated with treatment duration in multivariate analyses, overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib (cohort 1).
기간: From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).

Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1).

The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time:

PDC (%)=(No.days covered)/(No.days of interest)×100

From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause) (cohorts 1 and 2).
기간: From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause [i.e. deaths are not censored]), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause) (cohorts 1 and 2).
기간: From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation; that are considered serious during acalabrutinib±venetoclax treatment; and events of clinical interest (cohorts 1 and 2).
기간: From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation.

Adverse events that are considered serious (including fatal events) during acalabrutinib±venetoclax treatment, globally and treatment related (when available).

Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available).

They will be described overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 7월 11일

기본 완료 (추정된)

2029년 3월 31일

연구 완료 (추정된)

2029년 3월 31일

연구 등록 날짜

최초 제출

2023년 6월 29일

QC 기준을 충족하는 최초 제출

2023년 8월 10일

처음 게시됨 (실제)

2023년 8월 21일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 3일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • D8221R00003

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD 공유 기간

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 공유 액세스 기준

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .